Paper33485437
South Africa responds to new SARS-CoV-2 variant.
Makoni M. Lancet, 2021. Cited by 50 papers, by iCite.
Cite this record
ConductScience Library. South Africa responds to new SARS-CoV-2 variant. Papers, record 33485437. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33485437
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| COVID-19 | Major topic |
| Genetic Variation | Major topic |
| SARS-CoV-2 | Major topic |
| COVID-19 Vaccines | |
| Disease Transmission, Infectious | |
| Humans | |
| South Africa |
Source PubMed
Cited by44
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 50 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42074269 | Advances in Ozone-Based Inactivation of SARS-CoV-2: An Updated Review. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42074269 | PubMed |
| 39847599 | Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques. | PLoS Pathog | 2025 | https://conductscience.org/library/papers/39847599 | PubMed |
| 38746751 | Genomic surveillance and serological profile of SARS-CoV-2 variants circulating in Macaé and nearby cities, southeastern Brazil. | Front Microbiol | 2024 | https://conductscience.org/library/papers/38746751 | PubMed |
| 38472991 | Advances and Challenges in SARS-CoV-2 Detection: A Review of Molecular and Serological Technologies. | Diagnostics (Basel) | 2024 | https://conductscience.org/library/papers/38472991 | PubMed |
| 38149245 | Inducing enhanced neutralizing antibodies against broad SARS-CoV-2 variants through glycan-shielding multiple non-neutralizing epitopes of RBD. | Front Immunol | 2023 | https://conductscience.org/library/papers/38149245 | PubMed |
| 37708230 | From past to present: Exploring COVID-19 in Qatar's hemodialysis population across Omicron dominant and pre-Omicron periods. | PLoS One | 2023 | https://conductscience.org/library/papers/37708230 | PubMed |
| 37333517 | Multi-scale risk assessment and mitigations comparison for COVID-19 in urban public transport: A combined field measurement and modeling approach. | Build Environ | 2023 | https://conductscience.org/library/papers/37333517 | PubMed |
| 37275136 | Development of a universal real-time RT-PCR assay for detection of pan-SARS-coronaviruses with an RNA-based internal control. | Front Microbiol | 2023 | https://conductscience.org/library/papers/37275136 | PubMed |
| 37193986 | Clinical and laboratory features of SARS-CoV-2 variants across multiple rounds of pandemic waves in hospitalized children in an Iranian referral hospital. | BMC Pediatr | 2023 | https://conductscience.org/library/papers/37193986 | PubMed |
| 37015915 | Comprehensive structural analysis reveals broad-spectrum neutralizing antibodies against SARS-CoV-2 Omicron variants. | Cell Discov | 2023 | https://conductscience.org/library/papers/37015915 | PubMed |
| 36908419 | Modeling the positive testing rate of COVID-19 in South Africa using a semi-parametric smoother for binomial data. | Front Public Health | 2023 | https://conductscience.org/library/papers/36908419 | PubMed |
| 36534127 | The immunogenetics of COVID-19. | Immunogenetics | 2023 | https://conductscience.org/library/papers/36534127 | PubMed |
| 36298564 | The Epidemiological Features of the SARS-CoV-2 Omicron Subvariant BA.5 and Its Evasion of the Neutralizing Activity of Vaccination and Prior Infection. | Vaccines (Basel) | 2022 | https://conductscience.org/library/papers/36298564 | PubMed |
| 36256664 | Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2. | PLoS One | 2022 | https://conductscience.org/library/papers/36256664 | PubMed |
| 36116149 | Bioinformatics pipeline unveils genetic variability to synthetic vaccine design for Indian SARS-CoV-2 genomes. | Int Immunopharmacol | 2022 | https://conductscience.org/library/papers/36116149 | PubMed |
| 36097349 | The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity. | J Med Virol | 2023 | https://conductscience.org/library/papers/36097349 | PubMed |
| 36016342 | Disinfectants against SARS-CoV-2: A Review. | Viruses | 2022 | https://conductscience.org/library/papers/36016342 | PubMed |
| 35655960 | Evolutionary Traits and Genomic Surveillance of SARS-CoV-2 in South America. | Glob Health Epidemiol Genom | 2022 | https://conductscience.org/library/papers/35655960 | PubMed |
| 35501267 | Challenges of SARS-CoV-2 Omicron Variant and appropriate countermeasures. | J Microbiol Immunol Infect | 2022 | https://conductscience.org/library/papers/35501267 | PubMed |
| 35419205 | Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution. | Evol Med Public Health | 2022 | https://conductscience.org/library/papers/35419205 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33485437
GET https://conductscience.org/api/papers/v1/33485437/cited_by?page=2